General Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria
|
|
- Anis Wilkins
- 6 years ago
- Views:
Transcription
1 EDC-System Selection From the point of view of small to mid-size CROs Steffen König General Manager IST GmbH - Mannheim 26th Annual EuroMeeting March 2014 ACV, Vienna Austria
2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
3 Relevant CRO Facts Full-Service CRO 60 Employees 5 Statisticians 3 Statistical Programmer 11 Data Managers <10 ecrf Studies/year
4 Selection Process The vendor selection process aims at providing evidence that products and/or services delivered consistently meet particular requirements: Regulatory requirements Study- / Project requirements User requirements Budget requirements
5 Selection Process What do we expect from the EDC provider?
6 Environment Phase III Sponsor A NIS Phase I Sponsor B Lab-Data Questionnaires Med. Devices Phase II Sponsor C PASS Phase IV Sponsor D PASS Device Data Med. Devices Diagn. Tests
7 Administrative Requirements Beside standard administrative and standard functional requirements: Different environments must be reflected Clear cost structure Acceptance by sponsor Priority changes should be possible Changes in reasonable period of time Support of management processes
8 Selection Process What other considerations are important?
9 Vendor Characteristics Small EDC Provider Large EDC Provider Offices 1 5 Employees > Data center Languages 2 15 No. of projects per year > 500 Helpdesk 10 hrs at working days 7/24/365
10 Vendor Characteristics Small Vendor Has the vendor the capacity to setup the planned number of projects? Has the contact person a backup Does the vendor fulfill all technical reqirements? Is the vendor able to improve the services according to your requirements? Large Vendor Is the number of projects you ve planned of interest to the vendor? Do you have the same contact person and backup for all your projects Do you need all these opportunities? Is the vendor willing to improve the services according to your requirements?
11 At vendor site: Business Continuity Disaster recovery plan Back-ups in all key positions including management Mirror site Sound financial basis Escrow-Service
12 At CRO site: Business Continuity Emergency action plan Monitoring of Vendor (Risk Management) Personnel turnover, changes in management Major changes in company policy Changes in reliability or accuracy Yearly Feedback Meeting on Management level Use ESCROW service Have a second provider in reserve
13 Selection Process Experience from a vendor selection
14 Early Experience 1 st ecrf Selection Process (2006): Presentation of system at CRO by vendor Check if system meets our requirements Check of contract and costs Installation of ecrf test-system IT Test-Environment (Server etc.) Setup on local PCs for test-users
15 Early Experience Result (User): Very flexible All requirements fulfilled High performance Easy administration Clear cost structure This is the system we want Result (Auditor): Facilities not acceptable Back-ups not acceptable Documentation not acceptable SOP system not acceptable Business continuity not acceptable
16 Lessons Learned A clearly described selection process with involvement of all relevant parties is necessary to avoid: Mismatch with project needs Non-compliance with regulatory requirements Costs for needless installation and testing Redundant activities IT conflicts (capacity, system requirements)
17 Cross Functional Responsibilities All involved departments/functions must be involved in the selection process Task Study- / Project Requirements Technical Requirements (Hardware) Technical Requirements (Software) Budget Regulatory Requirements Vendor Qualification / Audit Responsible Project Manager IT Datamanagement / Project Manager Management / Finance QA QA
18 Relevant selection factors Vendor company size fits CRO size Number of projects Vendor capacity Technical requirements User requirements Communication (one face to the customer) Budget
19 Key to Success Cooperative partnership 1 Team: Sponsor & CRO & Vendor Open communication with visions how to improve processes Continuous improvement of technical services Mutual benefits
20 EDC-System Selection From the point of view of small to mid-size CROs Thank You!
Into the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith
Into the Clouds Understanding How Cloud Computing Will Effect the Future of Regulated Content Management Jennifer Goldsmith Vice President, Veeva Vault Veeva Systems The views and opinions expressed in
More informationPharmacovigilance Post July 2012 The new frontier
Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationIncorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance
Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The
More informationProject Management Standards Applied to Complex Clinical Trials. Disclaimer
Project Management Standards Applied to Complex Clinical Trials Alexander Gissler, PMP ProjectPharm Ltd., Owner & Director 1 Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationAndrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer
Fit for the future - A new strategic approach to Medical Information management within GSK Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here 1 Disclaimer The
More informationHigh Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationSharing Regulatory Intelligence: Best Practices and Case Studies
Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationDo Niche CROs have a Role in Drug Development?
Do Niche CROs have a Role in Drug Development? Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA President & CEO ECCRO 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationConstructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer
Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationesource What EDC Should Be Presenter: Ed Seguine President
esource What EDC Should Be Presenter: Ed Seguine President The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationHow to successfully Implement and Leverage the Regulatory Intelligence Function
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationUpdate on New MedDRA SOC Product issues
Update on New MedDRA SOC Product issues Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO ICSR Information Day 26 April 2016 London, UK Disclaimer The views and opinions expressed in the following
More informationQbD Approach and Regulatory Challenges in Japan
QbD Approach and Regulatory Challenges in Japan YOSHIHIRO MATSUDA Ph.D. Deputy Division Director Pharmaceuticals and Medical Devices Agency (PMDA) 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationThe Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports
The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd
More informationQPPV Association and Training Part 2 Session Introduction
QPPV Association and Training Part 2 Session Introduction Steve Douglas QPPV SGD Consulting Limited PrimeVigilance Ltd Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationEffective Project Leadership and Management: Disclaimer
Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationStakeholder education on biosimilar concepts - why does it matter globally?
Stakeholder education on biosimilar concepts - why does it matter globally? Dr Virginia Acha Director, Regulatory Policy Europe, Middle East and Africa Amgen 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationSPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs
SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs Doris Sincak Project Supervisor Sanofi Disclaimers DIA The views and opinions expressed in the following PowerPoint slides
More informationPresenter: Ejaz Butt
Presenter: Ejaz Butt Disclaimer The content and opinions expressed in the following PowerPoint slides are those of individuals who prepared the presentation and should not be attributed to Zigzag Associates
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationPromotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company
Promotional Materials and a Quality Management System Approach Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Disclaimer The views and opinions expressed in the
More informationHow can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise
How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation
More informationUsing etechnologies to Increase Efficiency and Quality in Regulatory Operations
Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Tim Powell Submissions Management Global Regulatory Affairs Disclaimer The views and opinions expressed in the following
More informationDelivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens
Delivering GxP compliant mobile applications a practical case study Presented by: Mark Stevens Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationImplementation of EU Falsified Medicines Directive
Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationHow to Implement a Successful e-archiving Function Within a Multinational Company
How to Implement a Successful e-archiving Function Within a Multinational Company Huguette BESSARD Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationNew Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following
More informationStructured Content Management [SCM]
Structured Content Management [SCM] Lessons learned from SCM implementations Shailesh Shah ArborSys Group Ole Rom Andersen CEO, DITA Exchange Inc. The views and opinions expressed in the following PowerPoint
More informationLabelling Harmonization 2011
Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationAcronis ACRONIS ACCESS ADVANCED
Acronis 2002-2014 ACRONIS ACCESS ADVANCED The proliferation of mobile devices into the enterprise is deeply impacting how people go about accomplishing their daily jobs. Mobile devices can t do everything
More informationProject Management Competencies. Disclaimer 28/06/2011
Project Management Competencies Martin D. Hynes III, Ph.D. Senior Director Product Research & Development Lilly Research Laboratories Eli Lilly and Company Indianapolis, IN Disclaimer The views and opinions
More informationPMDA Update. - New Regulation in Japan and Future Direction of PMDA
PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and
More informationAchieves International Standards
Rising to Excellence How a China CRO Achieves International Standards Helen Yin, VP & GM Tigermed-MacroStat Minzhi Liu, GM, MacroStat July 7 th, 2012 1 Outline Selecting excellent staff Training staff
More informationUtilities and Pitfalls of Modeling & Simulation in Pivotal Trials
Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials H.M. James Hung, Ph.D Div. of Biometrics I, OB/OTS/CDER U.S. Food and Drug Administration Presented in PhRMA/FDA Workshop, October 28,
More informationPMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More informationNAS and KAS Industry perspective
NAS and KAS Industry perspective Henk Schuring Group Vice President Regulatory Affairs Europe Genzyme Europe BV, Netherlands 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationQuality Management System Manual
SpecSys, Inc. recognizes its responsibility as a provider of quality products and services. To this end, SpecSys, Inc. has documented, implemented and maintains a System that complies with ISO 9001 2000.
More informationEugène van Puijenbroek, MD, PhD
Signal detection and signal management at the Netherlands Pharmacovigilance il Centre EudraVigilance Information Day 1 July 2009 Eugène van Puijenbroek, MD, PhD Disclaimer The views and opinions expressed
More informationEffective application of Risk Management techniques to Drug Safety: a pragmatic approach
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following
More informationData standardization and advancing regulatory science
Data standardization and advancing regulatory science Yoshiaki Uyama, Ph.D. Pharmaceuticals & Medical Devices Agency (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor,
More informationComputerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013
Computerised Systems Inspection Expectations ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Paul Moody, Inspector Slide 1 Presentation Contents Brief Introduction to the IMB Regulatory References
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationComputer System Validation & Backup
REFERENCE: VERSION NUMBER: 1.1 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Clinical Trials Officer REVIEWED BY: R&I Senior Team APPROVED BY: Deputy Director of Research
More informationQUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies
More informationQuality and Compliance: The Core of the Life Science Learning System
Quality and Compliance: The Core of the Life Science Learning System By Rob Sims, Director, Life Science, UL EduNeering Executive Summary: Quality and Compliance The Core of the Life Science Learning System
More informationTransforming Regulatory Affairs through Technology - End to End Tech Platform Approach
Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Peter Lassoff, PharmD, FTOPRA VP & Head, Global Regulatory Affairs IQVIA Disclaimer The views and opinions expressed
More information33rd SQA Annual Meeting, National Harbor, MA, USA Session C // Presentation C 2 28 March 2017 // 1:30 3:00 PM // V1.0
Computerized Systems Using Artificial Intelligence (AI) Components in a Regulated Environment: Implications on and Challenges of Establishing a Validated State René Kasan NNIT Switzerland AG Zürich, Switzerland
More informationProcedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011
Harmonization of Labeling Across Products with Same Active Moiety in the EU Procedures in Regard to Entire Product Information Texts Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Disclaimer The
More informationScope of Compellent Health Check Services
Service Description Dell Compellent SAN Health Check Service Overview This Service Description ( Service Description ) is entered among you the customer ( you or Customer ) and the Dell entity identified
More informationDesigning an Efficient IT Infrastructure. Lee Yee Ming 24 April 2014
Designing an Efficient IT Infrastructure Lee Yee Ming 24 April 2014 Designing an Efficient IT Infrastructure: Contents Identifying Needs 1. MDIC s Mandate and Operations 2. MDIC s IT Risk Management Designing
More informationPharmacovigilance in Asia: The China Perspectives. Disclaimer
Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in
More informationThe SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies
The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies By Rob Sims, UL Compliance to Performance When Life Sciences companies
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationFDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives
Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance
More informationOracle Health Sciences Adverse Event Integration Pack for Oracle Health Sciences InForm and Oracle Argus Safety
Oracle Health Sciences Adverse Event Integration Pack for Oracle Health Sciences InForm and Oracle Argus Safety Release Notes Release 1.0.2 E50819-01 December 2013 Overview The Oracle Health Sciences Adverse
More information11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf
11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf Penelope K. Manasco, M.D. CEO MANA RBM pmanasco@manarbm.com etmfs are rapidly replacing paper trial master
More informationTABLE OF CONTENTS WATER SERVICES ASSOCIATION OF AUSTRALIA PROCESS BENCHMARKING AUDIT PROTOCOLS COPYRIGHT:... 3
WATER SERVICES ASSOCIATION OF AUSTRALIA AUDIT PROTOCOL FOR THE AQUAMARK ASSET MANAGEMENT PROCESS BENCHMARKING PROJECT DECEMBER 2007 TABLE OF CONTENTS COPYRIGHT:... 3 1.0 INTRODUCTION:... 4 1.1 OVERVIEW...
More informationLabelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines
Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe
More informationRevision of the Variations Regulation. Key Principles and Guidelines Development CONTENT
DIA/EMEA/CMD(h) Conference London 26 October 2009 Revision of the Variations Regulation - Key Principles and Guidelines Development Hilde Boone EMEA 1 1 CONTENT 1. Background & revision status 2. Types
More informationVendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012
Vendor-Sponsor Successful Communication Nathalie Dutil Nov 2012 It s all about setting expectations. Lack of communication Miscommunication Presentation overview Strategic Sourcing Oversight Model Trust
More informationSCHOOL DISTRICT BUSINESS LEADER
SCHOOL DISTRICT BUSINESS LEADER Test Design The School District Business Leader assessment consists of two tests. Each test contains a section with multiple-choice questions and a section with written
More informationCentral Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses
Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses Michel Arnoult mmb@arnoult.org Stockholm 22 September 2015 Agenda DM Contribution to Data Quality
More informationCreating a Computer Security Incident Response Team Action Plan
Creating a Computer Security Incident Response Team CERT Training and Education Networked Systems Survivability Software Engineering Institute Carnegie Mellon University This material is approved for public
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationScientific Working Group on Digital Evidence
SWGDE Framework of a Quality Management System for Digital and Multimedia Disclaimer: As a condition to the use of this document and the information contained therein, the SWGDE requests notification by
More informationBlackBerry User Guide
Version 1.0 Copyright 2013, 2017, Oracle and/or its affiliates. All rights reserved. This software and related documentation are provided under a license agreement containing restrictions on use and disclosure
More informationCSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017
CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection
More informationOracle Communications Pricing Design Center
Oracle Communications Pricing Design Center Licensing Information User Manual Release 11.2 E98018-01 July 2018 Copyright 2018, Oracle and/or its affiliates. All rights reserved. This software and related
More informationBoard of Directors Performance Self-Evaluation Questionnaire
Board of Directors Performance Self-Evaluation Questionnaire Please check the number that best represents your opinion on each question or statement. In each case 1 is the least favorable response and
More informationectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA
ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL
Shaping the Future of Drug Development ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL Jim Baker Senior Vice President Clinical Research Services Cytel JIM BAKER Senior
More informationDevelopment of Orphan Drugs Regulatory Viewpoints from PMDA
Development of Orphan Drugs Regulatory Viewpoints from PMDA Ken Sakushima Office of Cellular and Tissue-based Products, Office of New Drug III Pharmaceuticals and Medical Devices Agency (PMDA) Disclaimer
More informationPMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA
PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed
More informationCopyright 2012, Oracle and/or its affiliates. All rights reserved.
1 Improving Data Management with Systems Integration and Next Generation Data Flow Rich Davies Director, Global Sales Consulting - HSGBU Safe Harbor Statement The following is intended to outline our general
More informationPanama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)
DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance
More informationCMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10
CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationYOUR SUCCESS IS OUR GOAL. Company Profile. Riyadh Jeddah Saudi Arabia IRSAA BUSINESS SOLUTIONS
YOUR SUCCESS IS OUR GOAL Company Profile Riyadh Jeddah Saudi Arabia IRSAA BUSINESS WWW.IRSAA.COM SOLUTIONS Company Summary . ABOUT IRSAA OUTSOURCING, BUSINESS SOLUTIONS & SERVICE PROVIDER IRSAA is the
More informationICT SPENDING PREDICTOR 2019
ICT SPENDING PREDICTOR 2019 TARGET Information pack Revolutionize your sales planning, target identification, and account planning Which prospects have the largest ICT budgets? How much more should our
More informationNTGA Compliance & Operational Manager Due Diligence Process
NORTHERN TRUST 2010 PROGRAM SOLUTIONS CONFERENCE Investment Solutions in an Uncertain World: WHAT S NEXT? NTGA Compliance & Operational Manager Due Diligence Process Allison K. Fraser VP & Sr. Compliance
More informationSentinel EMS. Integrating Sentinel EMS Server Into Your Existing Back-Office Systems
Sentinel EMS Integrating Sentinel EMS Server Into Your Existing Back-Office Systems Copyrights and Trademarks Gemalto 2017. All rights reserved. Gemalto, the Gemalto logo, are trademarks and service marks
More informationHealth Care CRM RFP Guide
Audience Rx Health Care CRM RFP Guide Key questions for identifying the right CRM provider 2017 Advisory Board All Rights Reserved 1 advisory.com Health Care CRM RFP Guide Key questions for identifying
More informationStandard Operating Procedures
Auditing of a Technology Vendor Checklist This checklist is intended to be a guide to planning your next audit. The items here should be evaluated for completeness. It is crucial for both Quality and the
More informationOracle Hospitality RES 3700 Enterprise Management. Installation Guide
Oracle Hospitality RES 3700 Enterprise Management Installation Guide Release 5.7 E95852-01 May 2018 Oracle Hospitality RES 3700 Enterprise Management Installation Guide, Release 5.7 E95852-01 Copyright
More informationPrimavera Project Delivery Application User s Guide
Primavera Project Delivery Application User s Guide Version 9.11.0.0 December 2012 Legal Notices Oracle Primavera Project Delivery Application Copyright 1998, 2012, Oracle and/or its affiliates. All rights
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationOn the Case: HCL Bekaert
Transitioning service providers and fine-tuning the global services approach Publication Date: 14 Aug 2014 Product code: IT0019-003359 Thomas Reuner Summary Catalyst Satisfaction with traditional, often
More informationCERT Resilience Management Model, Version 1.2
CERT Resilience Management Model, Asset Definition and Management (ADM) Richard A. Caralli Julia H. Allen David W. White Lisa R. Young Nader Mehravari Pamela D. Curtis February 2016 CERT Program Unlimited
More informationCore Abilities Assessment
Core Abilities Assessment Frequently Asked Questions 888-298-6227 TalentLens.com Copyright 2007 NCS Pearson, Inc. All rights reserved. Copyright 2007 by NCS Pearson, Inc. All rights reserved. No part of
More informationOECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use
OECD Working Group on Good Laboratory Practice Template for submission of comments on draft GLP Guidance Documents Instructions for Use 1. First, please complete the table below giving the full name of
More informationOracle Systems Optimization Support
Oracle Systems Optimization Support Oracle Systems Optimization Support offerings provide customers with welldefined packaged services. Let Oracle Advanced Customer Support help you make the most of your
More informationOracle Fusion Applications Workforce Development Guide. 11g Release 5 (11.1.5) Part Number E
Oracle Fusion Applications Workforce Development Guide 11g Release 5 (11.1.5) Part Number E22777-05 June 2012 Oracle Fusion Applications Workforce Development Guide Part Number E22777-05 Copyright 2011-2012,
More informationAgenda. Best Practices for Marketing Your Business Continuity Program Outside the Organization. Introduction
Best Practices for Marketing Your Business Continuity Program Outside the Organization Joanna D Aquanni SAS Brian Zawada Avalution Consulting Agenda Introduction Who Might Be Interested in Your Program
More informationOracle Systems Optimization Support
Oracle Systems Optimization Support Oracle Systems Optimization Support offering provides customers with welldefined packaged services. Let Oracle Advanced Customer Services help you make the most of your
More informationPMO Services Checklist
PMO Services Checklist by IMPACTbyLaura.com Services Checklist This resource is a list of possible services and categories that you can consider when determining how you will drive IMPACT with your PMO.
More informationMedical Information Role in the Pharmaceutical Industry
www.arisglobal.com A White Paper Presented By ArisGlobal Medical Information Role in the Pharmaceutical Industry by Ome Ogbru, PharmD, SME, Medical Communications & Sanjay Kumar D, Product Marketing Manager
More informationCloud & Accounting Treatment
Cloud & Accounting Treatment NASC 2018 Conference March 22, 2018 Yash Acharya, Director S&L Management Consulting Table of contents 1. 2. What is cloud? Current Guidance 3. Impact Current guidance 4. 5.
More informationFEATURE SCOPE DESCRIPTION PUBLIC Feature Scope Description SAP SE or an SAP affiliate company. All rights reserved.
FEATURE SCOPE DESCRIPTION PUBLIC 2018-09-21 2018 SAP SE or an SAP affiliate company. All rights reserved. THE BEST RUN Content 1 About this Document....3 2....4 2 P U B L I C Content 1 About this Document
More informationOracle. Adaptive Intelligent Apps for CX Getting Started with Adaptive Intelligent Sales 18.10
Oracle Adaptive Intelligent Apps for CX Getting Started with Adaptive Intelligent Sales 18.10 Part Number: E95993-04 Copyright 2018, Oracle and/or its affiliates. All rights reserved Authors: Adaptive
More information